Announcements
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
- Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
- Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
More ▼
Key statistics
As of last trade Alterity Therapeutics Ltd (PRNAF:PKC) traded at 0.0002, 0.00% above its 52-week low of 0.0002, set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.0002 |
Average volume | -- |
---|---|
Shares outstanding | 5.25bn |
Free float | 4.88bn |
P/E (TTM) | -- |
Market cap | 26.23m AUD |
EPS (TTM) | -0.005 AUD |
Data delayed at least 15 minutes, as of Feb 13 2024.
More ▼